First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression

PURPOSE: In the randomized phase IIb LUX-Lung 7 trial, afatinib significantly improved progression-free survival (PFS) and time-to-treatment failure vs gefitinib in patients with treatment-naïve epidermal growth factor receptor mutation-positive non-small cell lung cancer. We report post hoc analyse...

Descripción completa

Detalles Bibliográficos
Autores principales: Schuler, Martin, Tan, Eng-Huat, O’Byrne, Kenneth, Zhang, Li, Boyer, Michael, Mok, Tony, Hirsh, Vera, Yang, James Chih-Hsin, Lee, Ki Hyeong, Lu, Shun, Shi, Yuankai, Kim, Sang-We, Laskin, Janessa, Kim, Dong-Wan, Arvis, Catherine Dubos, Kölbeck, Karl, Massey, Dan, Märten, Angela, Paz-Ares, Luis, Park, Keunchil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2019
Materias:
Original Article - Clinical Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6527523/
https://www.ncbi.nlm.nih.gov/pubmed/30783814
http://dx.doi.org/10.1007/s00432-019-02862-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6527523/
https://www.ncbi.nlm.nih.gov/pubmed/30783814
http://dx.doi.org/10.1007/s00432-019-02862-x

Ejemplares similares